%0 Case Reports
%T Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction: A Case Report.
%A Endo Y
%A Kamo N
%A Kato A
%A Sato T
%A Okabe C
%A Furukawa S
%A Watanabe T
%A Soeda S
%J In Vivo
%V 38
%N 2
%D 2024 Mar-Apr
%M 38418162
%F 2.406
%R 10.21873/invivo.13527
%X <B>BACKGROUND: </B>Polyadenosine 5'-diphosphoribose polymerase inhibitors (PARP-Is) are novel, effective agents for treating newly diagnosed epithelial ovarian cancer (EOC). However, the effect of PARP-I on the progression of recurrent EOC has not yet been determined. In particular, there is limited evidence regarding retreatment with PARP-I for recurrent EOC that has progressed on PARP-I in the short term.<BR><B>METHODS: </B>A 69-year-old woman with a BRCA1 mutated EOC relapsed five months after starting olaparib maintenance following neoadjuvant chemotherapy and interval debulking surgery. Although the platinum-free interval was within six months, secondary cytoreductive surgery was performed because the tumor was locoregional. Following two cycles of weekly nedaplatin, niraparib induced a complete response, and the patient maintained a progression-free status for 15 months.<BR><B>CONCLUSIONS: </B>Even with short-term progression on PARP-I, local control combined with different platinum agents and PARP-I can be used to achieve good responses.